TCR-027-004 was selected as the lead PRAME-TCR based on the highest functional avidity, best capacity to secrete IFN-γ after stimulation with tumor cells, and strongest triggering of cytotoxicity, particularly against tumor cells with low antigen levels. Here, IFNG is linked to neoplasm.